دورية أكاديمية
أعرض في EDS

Quantitative muscle ultrasound as a disease biomarker in hereditary transthyretin amyloidosis with polyneuropathy.

التفاصيل البيبلوغرافية
العنوان: Quantitative muscle ultrasound as a disease biomarker in hereditary transthyretin amyloidosis with polyneuropathy.
المؤلفون: Tan SY; Department of Medicine, Neurology Unit, University of Malaya, Kuala Lumpur, Malaysia., Tan CY; Department of Medicine, Neurology Unit, University of Malaya, Kuala Lumpur, Malaysia. cytan@ummc.edu.my.; Department of Medicine, Faculty of Medicine, Universiti Malaya, Lembah Pantai, 50603, Kuala Lumpur, Malaysia. cytan@ummc.edu.my., Yahya MA; Neurophysiology Laboratory, University of Malaya Medical Centre, Kuala Lumpur, Malaysia., Low SC; Department of Medicine, Neurology Unit, University of Malaya, Kuala Lumpur, Malaysia., Shahrizaila N; Department of Medicine, Neurology Unit, University of Malaya, Kuala Lumpur, Malaysia., Goh KJ; Department of Medicine, Neurology Unit, University of Malaya, Kuala Lumpur, Malaysia.
المصدر: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology [Neurol Sci] 2024 Jul; Vol. 45 (7), pp. 3449-3459. Date of Electronic Publication: 2024 Jan 25.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer-Verlag Italia Country of Publication: Italy NLM ID: 100959175 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1590-3478 (Electronic) Linking ISSN: 15901874 NLM ISO Abbreviation: Neurol Sci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Milano, Italy : Springer-Verlag Italia, c2000-
مواضيع طبية MeSH: Amyloid Neuropathies, Familial*/diagnostic imaging , Ultrasonography* , Muscle, Skeletal*/diagnostic imaging , Muscle, Skeletal*/pathology , Polyneuropathies*/diagnostic imaging, Humans ; Male ; Female ; Middle Aged ; Aged ; Biomarkers ; Adult
مستخلص: Introduction: There is an increasing need for a reproducible and sensitive outcome measure in patients with hereditary transthyretin amyloidosis (ATTRv) with polyneuropathy (PN) due to the emergence of disease modifying therapies. In the current study, we aimed to investigate the role of quantitative muscle ultrasound (QMUS) as a disease biomarker in ATTRv-PN.
Methods: Twenty genetically confirmed ATTRv amyloidosis patients (nine symptomatic, 11 pre-symptomatic) were enrolled prospectively between January to March 2023. Muscle ultrasound was performed on six muscles at standardized locations. QMUS parameters included muscle thickness (MT) and muscle echo intensity (EI). Twenty-five age- and sex-matched healthy controls were recruited for comparison. Significant QMUS parameters were correlated with clinical outcome measures.
Results: Muscle volume of first dorsal interosseus (FDI) muscle [measured as cross-sectional area (CSA)] was significantly lower in symptomatic patients compared to healthy controls and pre-symptomatic carriers (98.3 ± 58.0 vs. 184.4 ± 42.5 vs. 198.3 ± 56.8, p < 0.001). EI of biceps and FDI for symptomatic ATTRv-PN patients were significantly higher compared to the other two groups (biceps: 76.4 ± 10.8 vs. 63.2 ± 11.5 vs. 59.2 ± 9.0, p = 0.002; FDI: 48.2 ± 7.5 vs. 38.8 ± 7.5 vs. 33.0 ± 5.3, p < 0.001). CSA of FDI and EI of biceps and FDI correlated with previous validated outcome measures [polyneuropathy disability score, neuropathy impairment score, Karnofsky performance scale, Rasch-built overall disability scale, European quality of life (QoL)-5 dimensions and Norfolk QoL questionnaire-diabetic neuropathy].
Conclusion: QMUS revealed significant difference between ATTRv amyloidosis patients and healthy controls and showed strong correlation with clinical outcome measures. QMUS serves as a sensitive and reliable biomarker of disease severity in ATTRv-PN.
(© 2024. Fondazione Società Italiana di Neurologia.)
References: Coelho T, Waddington Cruz M, Chao CC et al (2023) Characteristics of patients with hereditary transthyretin amyloidosis-polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an open-label phase 3 study of eplontersen. Neurol Ther 12(1):267–287. (PMID: 3652514010.1007/s40120-022-00414-z)
Obi CA, Mostertz WC, Griffin JM, Judge DP (2022) ATTR epidemiology, genetics, and prognostic factors. Methodist Debakey Cardiovasc J 18(2):17–26. (PMID: 35414855893238510.14797/mdcvj.1066)
Luigetti M, Romano A, Di Paolantonio A, Bisogni G, Sabatelli M (2020) Diagnosis and treatment of hereditary transthyretin amyloidosis (hATTR) polyneuropathy: current perspectives on improving patient care. Ther Clin Risk Manag 16:109–123. (PMID: 32110029704143310.2147/TCRM.S219979)
Low SC, Md Sari NA, Tan CY et al (2021) Hereditary transthyretin amyloidosis in multi-ethnic Malaysians. Neuromuscul Disord 31(7):642–650. (PMID: 3405942310.1016/j.nmd.2021.03.008)
Adams D, Ando Y, Beirao JM et al (2021) Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J Neurol 268(6):2109–2122. (PMID: 3190759910.1007/s00415-019-09688-0)
Obici L, Mussinelli R (2021) Current and emerging therapies for hereditary transthyretin amyloidosis: strides towards a brighter future. Neurotherapeutics 18(4):2286–2302. (PMID: 34850359880411910.1007/s13311-021-01154-y)
Simon NG, Noto YI, Zaidman CM (2016) Skeletal muscle imaging in neuromuscular disease. J Clin Neurosci 33:1–10. (PMID: 2761267010.1016/j.jocn.2016.01.041)
van Alfen N, Gijsbertse K, de Korte CL (2018) How useful is muscle ultrasound in the diagnostic workup of neuromuscular diseases? Curr Opin Neurol 31(5):568–574. (PMID: 3002873610.1097/WCO.0000000000000589)
Pillen S, Verrips A, van Alfen N, Arts IM, Sie LT, Zwarts MJ (2007) Quantitative skeletal muscle ultrasound: diagnostic value in childhood neuromuscular disease. Neuromuscul Disord 17(7):509–516. (PMID: 1753763510.1016/j.nmd.2007.03.008)
Zuberi SM, Matta N, Nawaz S, Stephenson JB, McWilliam RC, Hollman A (1999) Muscle ultrasound in the assessment of suspected neuromuscular disease in childhood. Neuromuscul Disord 9(4):203–207. (PMID: 1039974510.1016/S0960-8966(99)00002-4)
Pillen S, Boon A, Van Alfen N (2016) Muscle ultrasound. Handb Clin Neurol 136:843–853. (PMID: 2743044510.1016/B978-0-444-53486-6.00042-9)
Podnar S, Sarafov S, Tournev I, Omejec G, Zidar J (2017) Peripheral nerve ultrasonography in patients with transthyretin amyloidosis. Clin Neurophysiol 128(4):505–511. (PMID: 2822628610.1016/j.clinph.2017.01.013)
Salvalaggio A, Coraci D, Cacciavillani M et al (2021) Nerve ultrasound in hereditary transthyretin amyloidosis: red flags and possible progression biomarkers. J Neurol 268(1):189–198. (PMID: 3274960010.1007/s00415-020-10127-8)
Du K, Xu K, Cheng S et al (2021) Nerve ultrasound comparison between transthyretin familial amyloid polyneuropathy and chronic inflammatory demyelinating polyneuropathy. Front Neurol 12:632096. (PMID: 33716932795371610.3389/fneur.2021.632096)
Winter N, Vittore D, Gess B, Schulz JB, Grimm A, Dohrn MF (2021) New keys to early diagnosis: muscle echogenicity, nerve ultrasound patterns, electrodiagnostic, and clinical parameters in 150 patients with hereditary polyneuropathies. Neurotherapeutics 18(4):2425–2435. (PMID: 34708324880401010.1007/s13311-021-01141-3)
Shahrizaila N, Noto Y, Simon NG et al (2017) Quantitative muscle ultrasound as a biomarker in Charcot-Marie-Tooth neuropathy. Clin Neurophysiol 128(1):227–232. (PMID: 2794014710.1016/j.clinph.2016.11.010)
Cakar A, Durmus-Tekce H, Parman Y (2019) Familial Amyloid Polyneuropathy Noro Psikiyatr Ars 56(2):150–156. (PMID: 31223250)
Yamamoto S, Wilczek HE, Nowak G et al (2007) Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single-center experience over 16 years. Am J Transplant 7(11):2597–2604. (PMID: 1786806210.1111/j.1600-6143.2007.01969.x)
Aimo A, Rapezzi C, Perfetto F et al (2021) Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis. Eur J Clin Invest 51(11):e13598. (PMID: 33982288859639610.1111/eci.13598)
Berk JL, Suhr OB, Obici L et al (2013) Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 310(24):2658–2667. (PMID: 24368466413916410.1001/jama.2013.283815)
Coelho T, Maia LF, Martins da Silva A et al (2012) Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 79(8):785–792. (PMID: 22843282409887510.1212/WNL.0b013e3182661eb1)
Adams D, Gonzalez-Duarte A, O’Riordan WD et al (2018) Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 379(1):11–21. (PMID: 2997275310.1056/NEJMoa1716153)
Coelho T, Maurer MS, Suhr OB (2013) THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin 29(1):63–76. (PMID: 2319394410.1185/03007995.2012.754348)
Benson MD, Waddington-Cruz M, Berk JL et al (2018) Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 379(1):22–31. (PMID: 2997275710.1056/NEJMoa1716793)
Tan CY, Yahya MA, Goh KJ, Shahrizaila N (2023) Nerve ultrasound score in chronic inflammatory demyelinating polyneuropathy. Medicina 59:747. (PMID: 371097051014499310.3390/medicina59040747)
Adams D, Tournev IL, Taylor MS et al (2023) Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid 30(1):1–9. (PMID: 3587589010.1080/13506129.2022.2091985)
Adams D, Koike H, Slama M, Coelho T (2019) Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat Rev Neurol 15(7):387–404. (PMID: 3120930210.1038/s41582-019-0210-4)
Tozza S, Severi D, Spina E et al (2021) The neuropathy in hereditary transthyretin amyloidosis: a narrative review. J Peripher Nerv Syst 26(2):155–159. (PMID: 33960565836004410.1111/jns.12451)
Koike H, Misu K, Sugiura M et al (2004) Pathology of early- vs late-onset TTR Met30 familial amyloid polyneuropathy. Neurology 63(1):129–138. (PMID: 1524962210.1212/01.WNL.0000132966.36437.12)
Kollmer J, Hund E, Hornung B et al (2015) In vivo detection of nerve injury in familial amyloid polyneuropathy by magnetic resonance neurography. Brain 138(Pt 3):549–562. (PMID: 2552697410.1093/brain/awu344)
Vegezzi E, Cortese A, Bergsland N, Mussinelli R, Paoletti M, Solazzo F et al (2023) Muscle quantitative MRI as a novel biomarker in hereditary transthyretin amyloidosis with polyneuropathy: a cross-sectional study. J Neurol 270(1):328–339. (PMID: 3606481410.1007/s00415-022-11336-z)
Durelle C, Delmont E, Michel C, Trabelsi A, Hostin MA, Ogier A et al (2023) Eur J Neurol 30(10):3286–3295. (PMID: 3742289510.1111/ene.15970)
Salvalaggio A, Coraci D, Obici L, Cacciavillani M, Luigetti M, Mazzeo A et al (2022) Progressive brachial plexus enlargement in hereditary transthyretin amyloidosis. J Neurol 269:1905–1912. (PMID: 3441049410.1007/s00415-021-10754-9)
Granata G, Luigetti M, Coraci D, Del Grande A, Romano A, Bisogni G et al (2014) Ultrasound evaluation in transthyretin-related amyloid neuropathy. Muscle Nerve 50:372–376. (PMID: 2439546110.1002/mus.24168)
Leonardi L, Vanoli F, Fionda L, Loreti S, Garibaldi M, Morino S et al (2020) Nerve ultrasonography findings as possible pitfall in differential diagnosis between hereditary transthyretin amyloidosis with polyneuropathy and chronic inflammatory demyelinating polyneuropathy. Neurol Sci 41:3775–3778. (PMID: 3293635710.1007/s10072-020-04717-7)
Hanyu N, Ikeda S, Nakadai A, Yanagisawa N, Powell HC (1989) Peripheral nerve pathological findings in familial amyloid polyneuropathy: a correlative study of proximal sciatic nerve and sural nerve lesions. Ann Neurol 25(4):340–350. (PMID: 254069310.1002/ana.410250405)
Fujitake J, Mizuta H, Fuji H, Ishikawa Y, Katsuyama E, Takasu K et al (2003) Late-onset familial amyloid polyneuropathy: an autopsy study of two Japanese brothers. Amyloid 10(3):198–205. (PMID: 1464003310.3109/13506120308999001)
Cartwright MS, Kwayisi G, Griffin LP et al (2013) Quantitative neuromuscular ultrasound in the intensive care unit. Muscle Nerve 47(2):255–259. (PMID: 2304198610.1002/mus.23525)
Sarwal A, Parry SM, Berry MJ et al (2015) Interobserver reliability of quantitative muscle sonographic analysis in the critically ill population. J Ultrasound Med 34(7):1191–1200. (PMID: 2611262110.7863/ultra.34.7.1191)
O’Brien TG, Cazares Gonzalez ML, Ghosh PS, Mandrekar J, Boon AJ (2017) Reliability of a novel ultrasound system for gray-scale analysis of muscle. Muscle Nerve 56(3):408–412. (PMID: 2797784610.1002/mus.25513)
Baston CM, Gellhorn AC, Hough CL, Bunnell AE (2022) Interrater reliability of quantitative ultrasound measures of muscle in critically ill patients. PM R 14(2):183–189. (PMID: 3501418210.1002/pmrj.12758)
Zaidman CM, Wu JS, Wilder S, Darras BT, Rutkove SB (2014) Minimal training is required to reliably perform quantitative ultrasound of muscle. Muscle Nerve 50(1):124–128. (PMID: 24218288410288410.1002/mus.24117)
فهرسة مساهمة: Keywords: Amyloidosis; Hereditary transthyretin amyloidosis; Muscle ultrasound; Neuromuscular ultrasound; Ultrasound
المشرفين على المادة: 0 (Biomarkers)
SCR Disease Name: Amyloidosis, Hereditary, Transthyretin-Related
تواريخ الأحداث: Date Created: 20240125 Date Completed: 20240614 Latest Revision: 20240626
رمز التحديث: 20240626
DOI: 10.1007/s10072-024-07340-y
PMID: 38270729
قاعدة البيانات: MEDLINE
الوصف
تدمد:1590-3478
DOI:10.1007/s10072-024-07340-y